BioMarin Pharmaceutical Dividend
Dividend criteria checks 0/6
BioMarin Pharmaceutical does not have a record of paying a dividend.
Key information
n/a
Dividend yield
n/a
Payout ratio
Industry average yield | 2.9% |
Next dividend pay date | n/a |
Ex dividend date | n/a |
Dividend per share | n/a |
Earnings per share | US$0.88 |
Dividend yield forecast in 3Y | 0% |
Recent dividend updates
No updates
Recent updates
BioMarin Pharmaceutical Inc.'s (NASDAQ:BMRN) Shares Lagging The Industry But So Is The Business
Apr 21Is BioMarin Pharmaceutical (NASDAQ:BMRN) Using Too Much Debt?
Mar 30BioMarin Pharmaceutical: Still Has A Lot Of Room For Growth
Feb 29BioMarin's Growth Potential And Valuation: Is Now The Right Time To Invest?
Jan 19Little Excitement Around BioMarin Pharmaceutical Inc.'s (NASDAQ:BMRN) Revenues
Jan 05Is BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Trading At A 49% Discount?
Dec 15Is BioMarin Pharmaceutical (NASDAQ:BMRN) Using Too Much Debt?
Nov 03Is BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Trading At A 42% Discount?
Aug 09We Think BioMarin Pharmaceutical (NASDAQ:BMRN) Can Stay On Top Of Its Debt
Jul 18BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Shares Could Be 42% Below Their Intrinsic Value Estimate
May 09Why Investors Shouldn't Be Surprised By BioMarin Pharmaceutical Inc.'s (NASDAQ:BMRN) Low P/S
Apr 18These 4 Measures Indicate That BioMarin Pharmaceutical (NASDAQ:BMRN) Is Using Debt Safely
Mar 27An Intrinsic Calculation For BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Suggests It's 39% Undervalued
Jan 09BioMarin redesigns organization, will lay off about 4% of its workforce
Oct 07BioMarin resubmits biologics license application to FDA for hemophilia A gene therapy
Sep 29BioMarin touts report on cost effectiveness of gene therapy Roctavian for hemophilia A
Sep 15BioMarin to resubmit hemophilia therapy for FDA approval after EU nod
Aug 25BioMarin may be an activist target after 13-F filings
Aug 15BioMarin (BMRN) boosts 2022 top and bottom line guidance on back of product sales growth
Aug 03BioMarin: More Growth
Jul 21BioMarin's Solid Pipeline Bears The First Fruit
Jun 27Would BioMarin Pharmaceutical (NASDAQ:BMRN) Be Better Off With Less Debt?
May 25BioMarin: A Good Anchor For Your Biotech Portfolio
May 10BioMarin: Keep Waiting For The Growth
Mar 03BioMarin Pharmaceutical (NASDAQ:BMRN) Has Debt But No Earnings; Should You Worry?
Feb 24BioMarin's Win In Phase 3 Hemophilia Study Makes Its Investment Case Stronger
Jan 11Stability and Growth of Payments
Fetching dividends data
Stable Dividend: Insufficient data to determine if BMRN's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if BMRN's dividend payments have been increasing.
Dividend Yield vs Market
BioMarin Pharmaceutical Dividend Yield vs Market |
---|
Segment | Dividend Yield |
---|---|
Company (BMRN) | n/a |
Market Bottom 25% (US) | 1.5% |
Market Top 25% (US) | 4.7% |
Industry Average (Biotechs) | 2.9% |
Analyst forecast in 3 Years (BMRN) | 0% |
Notable Dividend: Unable to evaluate BMRN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate BMRN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate BMRN's payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as BMRN has not reported any payouts.